Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma

Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma

US Patent 7384926 · Granted Jun 10, 2008

Estimated economic value: $301,887,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Devices, systems, and methods for modeling ocular translaminar pressure gradient2023
Transferrin/transferrin receptor-mediated siRNA delivery2018
Methods of treating ophthalmic diseases using NPR-B agonists2017
RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions2017
Transferrin/transferrin receptor-mediated siRNA delivery2017
RNAI-mediated inhibition of frizzled related protein-1 for treatment of glaucoma2017
RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions2016
RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular a2016
Methods of treating ophthalmic diseases using NPR-B agonists2015
RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions2015
RNAi-related inhibition of TNF alpha signaling pathway for treatment of ocular a2015
Transferrin/transferrin receptor-mediated siRNA delivery2015